#AUA14 - Targeted magnetic resonance imaging/ultrasound fusion biopsy is a significantly better predictor of total prostate cancer tumor volume than random 12-core biopsy - Session Highlights

ORLANDO, FL USA (UroToday.com) - Tumor volume is an important prognostic factor for men with prostate cancer, yet it has proven difficult to measure pre-operatively. Random biopsy core length and percentage of core involvement have both been used as proxies, but these measures suffer from poor accuracy. Okoro et al. from the National Cancer Institute now report that targeted, image-guided biopsy can provide a significantly better measure of prostate cancer tumor volume.

auaThe authors randomly selected 100 patients who had undergone multiparametric prostate MRI (MP-MRI) followed by MRI/US fusion-guided biopsy, as well as extended sextant 12-core biopsy. Radiologic tumor volume was determined by manually sectioning each tumor using iCAD software, given that this has been shown to correlate well with volume noted on whole mount pathology at radical prostatectomy. Tumor burden on targeted and random biopsy cores was then compared to tumor volume measured on MRI. Targeted biopsy tumor burden correlated well with estimated tumor volume, while random biopsy percent core involvement and absolute mm of cancer did not. Targeted biopsy also detected clinically significant (> 500 mm3) tumors with a 70% accuracy, as compared to 44% for random biopsy.

The authors conclude that targeted biopsy tumor burden provides an accurate, practical pre-operative measure of prostate cancer tumor burden. Such knowledge may present an important improvement in the risk stratification of men with prostate cancer, especially in those men in which such metrics are an essential component to treatment planning such as active surveillance and potentially focal therapy.

Presented by Chionyerem Okoro, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

National Cancer Institute (NCI), Bethesda, MD USA

Written by Dima Raskolnikov, National Cancer Institute (NCI)

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland